Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and ...
HCW Biologics Inc. and WY Biotech Co., Ltd. have finalized a licensing agreement for the development and commercialization of HCW11-006, a novel immunotherapy targeting age-related diseases and cancer ...
"Our vision is to turn the world's most powerful photosynthetic cell into a platform for scalable drug production that could ...
SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Shanghai ZJ Bio-Tech technology Co., Ltd. (hereinafter referred to ...
HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 millionTrimmune will hold exclusive worldwide license for rights ...
AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...
PDUFA action date set for August 23, 2026If approved, DTX401 will be the first treatment to address the underlying cause of GDSIaNOVATO, Calif., ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
The U.S. Food and Drug Administration (FDA) announced on Wednesday (October 29) a plan to streamline the approval process for biosimilars, which are generic versions of complex biological drugs. These ...
Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results